<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05610865</url>
  </required_header>
  <id_info>
    <org_study_id>CEMB-SC02</org_study_id>
    <nct_id>NCT05610865</nct_id>
  </id_info>
  <brief_title>Efficacy of Adipose Tissue Derived Stem Cells for the Treatment of Diabetic Foot Ulcers</brief_title>
  <official_title>Autologous Adipose Tissue Derived Stromal Vascular Fraction Versus Cultured Adipose Derived Stem Cells for the Treatment of Chronic Diabetic Wounds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of the Punjab</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre of Excellence in Molecular Biology, University of the Punjab, Lahore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Higher Education Commission (Pakistan)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jinnah Burn and Reconstructive Surgery Centre, Lahore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of the Punjab</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the therapeutic efficacy of uncultured adipose derived&#xD;
      stromal vascular fraction (SVF) and cultured adipose derived stem cells (ASCs) both&#xD;
      supplemented with platelet rich plasma (PRP) to treat chronic diabetic foot ulcers. It will&#xD;
      increase the pragmatic potential of both types of cells as PRP is rich in survival and&#xD;
      chemotactic factors. Moreover, the autologous nature of the proposed study will ensure safety&#xD;
      of its use in diabetic patients and will unveil the more effective therapeutic option for&#xD;
      treatment of foot ulcer wounds.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Under local or general anesthesia, autologous fat will be harvested by using a manual&#xD;
      aspiration or syringe-assisted technique. SVF and ASCs isolation from autologous&#xD;
      lipoaspirates will be done by enzymatic digestion method (collagenase Type-1 solution for 45&#xD;
      minutes at 37Â°C). Cell quality assessment will be done prior to transplantation by trypan&#xD;
      blue exclusion assay and total populations and fractions of cells identified by&#xD;
      immunocytochemistry / flow cytometry. PRP will be derived by centrifugation from 50-100ml&#xD;
      blood collected in anticoagulant carrying bag, from patient at the day of transplantation.&#xD;
      The injection volume will depend on the wound area of each patient. 2 million cells/ 0.5 ml&#xD;
      PRP will be mixed, transferred to 1 cc syringes and injected / cm2 intradermally at the&#xD;
      border zone &amp; inside of wound surface bed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Interview and visual inspection of ulcers recovery rate</measure>
    <time_frame>3 months</time_frame>
    <description>This will be done in terms of diameter (cm2) of wounds, monitored in both cell transplanted and standard care patients after week interval till 3 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentages (%) of wound closure rate (with respect to time) will be assessed.</measure>
    <time_frame>3 months</time_frame>
    <description>Change in wound size (cm2) will be determined</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Diabetic Foot Ulcer</condition>
  <condition>Diabetes Mellitus</condition>
  <condition>Diabetic Foot</condition>
  <condition>Diabetic Foot Infection</condition>
  <condition>Diabetic Foot Ulcer Neuropathic</condition>
  <condition>Foot Ulcer Due to Type 1 Diabetes Mellitus</condition>
  <condition>Foot Ulcer Due to Type 2 Diabetes Mellitus</condition>
  <condition>Foot Ulcer</condition>
  <condition>Diabetes Complications</condition>
  <condition>Chronic Diabetic Ulcer of Left Foot</condition>
  <condition>Chronic Diabetic Foot Ulcer of Right Foot</condition>
  <arm_group>
    <arm_group_label>Control; Standard-of-care management</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Saline dressing will be done as a routine care management.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Only PRP injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Only PRP will be injected at the wound site.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRP + SVF injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SVF pellet mixed with PRP will be injected at the wound site after adjusting number of cells.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRP + ASCs injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cultured ASCs mixed with PRP will be injected at the wound site after adjusting number of cells.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control; Standard-of-care management</intervention_name>
    <description>Patients will undergo conventional wound care management.</description>
    <arm_group_label>Control; Standard-of-care management</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Only PRP injection</intervention_name>
    <description>Only PRP injected / cm2 intradermally at the border zone &amp; inside of wound surface bed.</description>
    <arm_group_label>Only PRP injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PRP + SVF injection</intervention_name>
    <description>Uncultured cells (SVF) along PRP were mixed, transferred to 1 cc syringes and injected / cm2 intradermally at the border zone &amp; inside of wound surface bed.</description>
    <arm_group_label>PRP + SVF injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PRP + ASCs injection</intervention_name>
    <description>Cultured ASCs along PRP were mixed, transferred to 1 cc syringes and injected / cm2 intradermally at the border zone &amp; inside of wound surface bed.</description>
    <arm_group_label>PRP + ASCs injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 1 or Type 2 Diabetes Mellitus&#xD;
&#xD;
          -  Age 20-60 years (Male/Female)&#xD;
&#xD;
          -  Body mass index 20-30 kg/m2&#xD;
&#xD;
          -  Suitable for liposuction&#xD;
&#xD;
          -  Condition or Disease: Diabetic Neuropathy&#xD;
&#xD;
          -  Wound Type: Chronic foot ulcer&#xD;
&#xD;
          -  Approx. wound area: 2 cm2 - 8 cm2&#xD;
&#xD;
          -  Wound Condition should be of Wagner's grade I (Limited to soft tissue)&#xD;
&#xD;
          -  Duration of wound persistence: 6-24 Weeks&#xD;
&#xD;
          -  Transcutaneous oxygen pressure &gt; 30 mmHg, and an ankle brachial pressure index &gt; 0.5.&#xD;
&#xD;
          -  Already following an adequate off-loading method&#xD;
&#xD;
          -  Provided signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled hyperglycemia (HbAlc &gt; 9%)&#xD;
&#xD;
          -  Presence of severe clinical sign of infection&#xD;
&#xD;
          -  Inability to tolerate off-loading, and poor prognosis diseases including malignant&#xD;
             tumors.&#xD;
&#xD;
          -  Serious chronic disease i.e hepatic, heart, renal, pulmonary diseases&#xD;
&#xD;
          -  Patients with critical limb ischemia and osteomylitis&#xD;
&#xD;
          -  Withdrawal of informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Azra Mehmood, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center of Excellence in Molecular Biology (CEMB, University of the Punjab, Lahore</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sheikh Riazuddin, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Jinnah Burn and Reconstructive Surgery Center (JB&amp;RSC), Lahore</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Azra Mehmood, PhD</last_name>
    <phone>+92-333-4107008</phone>
    <email>azra_mehmood@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amna Arif, M.Phil.</last_name>
    <phone>+92-333-4161068</phone>
    <email>amnaarif.qureshi@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stem Cell Laboratory, Jinnah Burn and Reconstructive Surgery Center (JB&amp;RSC)</name>
      <address>
        <city>Lahore</city>
        <state>Punjab</state>
        <zip>54550</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Moazzam Nazeer Tarar, Plastic Surgeon MBBS/ FRCS</last_name>
      <phone>+92-300-8423139</phone>
      <email>mntarar@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <reference>
    <citation>Shao S, Pan R, Chen Y. Autologous Platelet-Rich Plasma for Diabetic Foot Ulcer. Trends Endocrinol Metab. 2020 Dec;31(12):885-890. doi: 10.1016/j.tem.2020.10.003. Epub 2020 Nov 13.</citation>
    <PMID>33199085</PMID>
  </reference>
  <reference>
    <citation>Nolan GS, Smith OJ, Heavey S, Jell G, Mosahebi A. Histological analysis of fat grafting with platelet-rich plasma for diabetic foot ulcers-A randomised controlled trial. Int Wound J. 2022 Feb;19(2):389-398. doi: 10.1111/iwj.13640. Epub 2021 Jun 24.</citation>
    <PMID>34169656</PMID>
  </reference>
  <reference>
    <citation>Carstens MH, Quintana FJ, Calderwood ST, Sevilla JP, Rios AB, Rivera CM, Calero DW, Zelaya ML, Garcia N, Bertram KA, Rigdon J, Dos-Anjos S, Correa D. Treatment of chronic diabetic foot ulcers with adipose-derived stromal vascular fraction cell injections: Safety and evidence of efficacy at 1 year. Stem Cells Transl Med. 2021 Aug;10(8):1138-1147. doi: 10.1002/sctm.20-0497. Epub 2021 Apr 7.</citation>
    <PMID>33826245</PMID>
  </reference>
  <reference>
    <citation>Qin HL, Zhu XH, Zhang B, Zhou L, Wang WY. Clinical Evaluation of Human Umbilical Cord Mesenchymal Stem Cell Transplantation After Angioplasty for Diabetic Foot. Exp Clin Endocrinol Diabetes. 2016 Sep;124(8):497-503. doi: 10.1055/s-0042-103684. Epub 2016 May 24.</citation>
    <PMID>27219884</PMID>
  </reference>
  <reference>
    <citation>Han SK, Kim HR, Kim WK. The treatment of diabetic foot ulcers with uncultured, processed lipoaspirate cells: a pilot study. Wound Repair Regen. 2010 Jul-Aug;18(4):342-8. doi: 10.1111/j.1524-475X.2010.00593.x. Epub 2010 May 11.</citation>
    <PMID>20492632</PMID>
  </reference>
  <reference>
    <citation>Didangelos T, Koliakos G, Kouzi K, Arsos G, Kotzampassi K, Tziomalos K, Karamanos D, Hatzitolios AI. Accelerated healing of a diabetic foot ulcer using autologous stromal vascular fraction suspended in platelet-rich plasma. Regen Med. 2018 Apr;13(3):277-281. doi: 10.2217/rme-2017-0069. Epub 2018 May 1.</citation>
    <PMID>29715071</PMID>
  </reference>
  <reference>
    <citation>Prakasam N, Prabakar MS, Reshma S, Loganathan K, Senguttuvan K. A clinical study of platelet rich plasma versus conventional dressing in management of diabetic foot ulcers. International Surgery Journal. 2018 Sep 25;5(10):3210-6.</citation>
  </reference>
  <reference>
    <citation>Alvaro-Afonso FJ, Sanz-Corbalan I, Lazaro-Martinez JL, Kakagia D, Papanas N. Adipose-Derived Mesenchymal Stem Cells in the Treatment of Diabetic Foot Ulcers: A Review of Preclinical and Clinical Studies. Angiology. 2020 Oct;71(9):853-863. doi: 10.1177/0003319720939467. Epub 2020 Jul 29.</citation>
    <PMID>32723090</PMID>
  </reference>
  <reference>
    <citation>Khan A, Junaid N. Prevalence of diabetic foot syndrome amongst population with type 2 diabetes in Pakistan in primary care settings. J Pak Med Assoc. 2017 Dec;67(12):1818-1824.</citation>
    <PMID>29256523</PMID>
  </reference>
  <reference>
    <citation>Yin S, Yang X, Bi H, Zhao Z. Combined Use of Autologous Stromal Vascular Fraction Cells and Platelet-Rich Plasma for Chronic Ulceration of the Diabetic Lower Limb Improves Wound Healing. Int J Low Extrem Wounds. 2021 Jun;20(2):135-142. doi: 10.1177/1534734620907978. Epub 2020 Mar 4.</citation>
    <PMID>32131655</PMID>
  </reference>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>October 26, 2022</study_first_submitted>
  <study_first_submitted_qc>November 3, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2022</study_first_posted>
  <last_update_submitted>November 3, 2022</last_update_submitted>
  <last_update_submitted_qc>November 3, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of the Punjab</investigator_affiliation>
    <investigator_full_name>Azra Mehmood</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Stromal vascular fraction (SVF), Adipose derived stem cells (ASCs), Diabetic foot ulcer (DFU), Platelet rich plasma (PRP)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Diabetes Complications</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

